Viralytics Ltd's (AX:VLA)Cavatak continues to impress, with a 100% disease control rate in 10 patients (seven objective responses) in combination with Keytruda in the CAPRA Phase Ib study. Furthermore, in the MITCI Phase Ib trial Cavatak, in combination with Yervoy, achieved a 50% response rate in the first 18 patients treated, which is an impressive response rate in a heavily pre-treated population. The encouraging results are a good sign for the ongoing trials of Cavatak and are likely to be of great interest to potential partners. We have increased our anticipated deal value assumptions for Viralytics following recent deals in oncolytic virotherapy, which lifts our valuation to A$385m or A$1.60/share.
Impressive preliminary data from MITCI and CAPRA
Updated results from the ongoing MITCI and CAPRA Phase Ib trials of Cavatak in combination with immune checkpoint inhibitors (ICIs) Yervoy and Keytruda, respectively, were presented at SITC in November 2016. All 10 patients showed a disease control rate in the CAPRA study evaluating intratumoral Cavatak in combination with Keytruda in advanced melanoma; seven of 10 patients (70%) showed an objective response rate and 30% had stable disease. In the MITCI trial, 9/18 (50%) patients with advanced melanoma had objective responses with Cavatak in combination with Yervoy. This compares favourably with reported response rates of 28% for Cavatak, 11% for Yervoy and 33% for Keytruda, as single agents.
To read the entire report Please click on the pdf File Below